Thyroid eye disease can cause eye discomfort and other symptoms that may make it hard to sleep. Managing these symptoms and addressing underlying thyroid conditions can help. Thyroid eye disease ...

The most useful biomarker for extraocular muscle enlargement in thyroid eye disease (TED) is unclear. According to this study, higher thyroid-stimulating antibody (TSAb) levels and older age were ...

Fibroblasts from patients with TED secrete active PAPP-A and are stimulated by proinflammatory cytokines, namely tumor necrosis factor (TNF)-α and interleukin (IL)-1β. Novel therapeutic agents may be ...

Please provide your email address to receive an email when new articles are posted on . Thyroid eye disease treatments have evolved significantly in recent years. Work is still needed to find durable, ...

As mentioned in Overview, most thyroid eye disease (TED) cases are closely related to hyperthyroidism. Approximately 85% of patients with TED develop the disease around 18 months before or after the ...

(Reuters) -Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the ...

Credit: Shutterstock. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. The Indications and Usage section of the Tepezza ® (teprotumumab-trbw) prescribing information has been ...

Annie Larsson, 40, is no stranger to chronic conditions. She was diagnosed with type 1 diabetes at a young age and had it “completely managed” for years. Then, right before the Covid pandemic began, ...

Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have identified new underlying mechanisms of proptosis, or bulging of the eyes, in patients with acute thyroid eye ...

BOSTON—Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ...

Active TED patients showed higher thyrotropin receptor antibody levels and increased DCP vessel density.